In Russia 2018 and 2019 have been interesting years for patent litigation. A number of revolutionary rulings were made in favor of international pharma producers while the local generic producers fiercely fought against innovators' attempts to enforce IP rights. For the first time Russian courts allowed international pharma producers to bring action based on a mere threat of patent infringement (rather than actual patent infringement). This has significantly broadened the legal tools available to pharma businesses for patent rights protection and, in particular, created a legal basis for obtaining permanent injunction against generic product before its launch. In practice, this means that patentees no longer have to wait until the infringement is actually happening in order to claim.
To read the full article click here
The content of this article is intended to provide a general guide to the subject matter. Specialist advice should be sought about your specific circumstances.